These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9179059)

  • 1. Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay.
    Brouillet JP; Dufour F; Lemamy G; Garcia M; Schlup N; Grenier J; Mani JC; Rochefort H
    Cancer; 1997 Jun; 79(11):2132-6. PubMed ID: 9179059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and clinical significance of cathepsin D in breast cancer metastasis.
    Garcia M; Platet N; Liaudet E; Laurent V; Derocq D; Brouillet JP; Rochefort H
    Stem Cells; 1996 Nov; 14(6):642-50. PubMed ID: 8948022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells.
    Capony F; Rougeot C; Montcourrier P; Cavailles V; Salazar G; Rochefort H
    Cancer Res; 1989 Jul; 49(14):3904-9. PubMed ID: 2736531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
    Merseburger AS; Hennenlotter J; Stenzl A; Beger G; Rinnab L; Kuczyk MA; Kuefer R
    Urol Int; 2007; 79(1):41-3. PubMed ID: 17627167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
    Rochefort H
    C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous cell carcinoma of the vulva. Expression of tumor proteases cathepsin-D and pro-cathepsin-L.
    Hantschmann P; Beysiegel S; Kurzl R
    J Reprod Med; 1998 Nov; 43(11):933-42. PubMed ID: 9839260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
    Alix-Panabières C; Brouillet JP; Fabbro M; Yssel H; Rousset T; Maudelonde T; Choquet-Kastylevsky G; Vendrell JP
    J Immunol Methods; 2005 Apr; 299(1-2):177-88. PubMed ID: 15914200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical visualisation of cathepsin-D expression in breast cancer.
    Barthell E; Mylonas I; Shabani N; Kunze S; Kuhn C; Jeschke U; Friese K
    Anticancer Res; 2007; 27(4A):2035-9. PubMed ID: 17649818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of cathepsin D and alpha(1)-antitrypsin in the blood serum of patients with mammary carcinoma.
    Wozniak A; Mila-Kierzenkowska C; Schachtschabel DO; Wozniak B; Rozwodowska M; Drewa T; Drewa S; Sir J; Sir I; Maciak R; Krzyzynska-Malinowska E
    Exp Oncol; 2005 Sep; 27(3):233-7. PubMed ID: 16244588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
    Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
    Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Western blotting and enzymatic activity analysis of cathepsin D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls.
    Schultz DC; Bazel S; Wright LM; Tucker S; Lange MK; Tachovsky T; Longo S; Niedbala S; Alhadeff JA
    Cancer Res; 1994 Jan; 54(1):48-54. PubMed ID: 8261461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
    Schwarzenbach H; Müller V; Stahmann N; Pantel K
    Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin D expression in renal cell cancer-clinical implications.
    Merseburger AS; Hennenlotter J; Simon P; Ohneseit PA; Kuehs U; Kruck S; Koch E; Vogel U; Stenzl A; Kuczyk MA
    Eur Urol; 2005 Sep; 48(3):519-26. PubMed ID: 16115525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.
    Briozzo P; Morisset M; Capony F; Rougeot C; Rochefort H
    Cancer Res; 1988 Jul; 48(13):3688-92. PubMed ID: 3378211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum big endothelin-1 levels in female patients with breast cancer.
    Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
    Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients.
    Bosscher JR; Gerçel-Taylor C; Watkins CS; Taylor DD
    Gynecol Oncol; 2001 May; 81(2):138-43. PubMed ID: 11330940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.